Research is being conducted to refine the role of immune checkpoint inhibitors in bladder cancer treatment. Studies are exploring various aspects, including augmentation strategies, biomarkers, and gene expression, to improve immunotherapy response and effectiveness. The scope of the research appears to be broad, with some studies focusing on bladder cancer specifically, while others discuss immune checkpoint inhibitors in a more general cancer therapy context.